Bhavini Mishra, Sanket Koul

Stories by Bhavini Mishra, Sanket Koul

Noida International Airport: Property Prices Soar Along Yamuna Expressway

Noida International Airport: Property Prices Soar Along Yamuna Expressway

Rediff.com   6 days ago

The inauguration of Noida International Airport (NIA) is set to significantly increase property values in micro-markets along the Yamuna Expressway, with projections indicating a 28 per cent rise for plots and 22 per cent for apartments over the next two years, according to Colliers.

Women Lawyers Face Steep Career Barriers

Women Lawyers Face Steep Career Barriers

Rediff.com   26 Mar 2026

Nearly two-thirds (63.7 per cent) said they had, at some stage, found the profession discouraging.

Centre Cracks Down on GLP-1 Drug Misuse

Centre Cracks Down on GLP-1 Drug Misuse

Rediff.com   25 Mar 2026

Inspections conducted across 49 entities including pharmacies, wholesalers, and clinics to detect violations and misleading marketing practices.

Semaglutide Ruling Sparks Generic Pharma Boom

Semaglutide Ruling Sparks Generic Pharma Boom

Rediff.com   24 Mar 2026

At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.

Anil Ambani seeks debt treatment like Sterling's Sandesaras'

Anil Ambani seeks debt treatment like Sterling's Sandesaras'

Rediff.com   24 Mar 2026

Industrialist Anil Ambani has approached the Supreme Court seeking a court-facilitated debt resolution similar to the one provided to Sterling group's Nitin and Chetan Sandesara, and five other members of their families.

Reality check gets India on investors' realty list

Reality check gets India on investors' realty list

Rediff.com   23 Mar 2026

Escalating geopolitical tensions in West Asia are prompting investors with exposure to Dubai's real estate market to reassess their portfolios. And, in this rejig, India is emerging as a stable destination for capital investment and long-term growth.

SC wants Centre to bring law on paternity leave

SC wants Centre to bring law on paternity leave

Rediff.com   18 Mar 2026

The Supreme Court on Tuesday called on the Union government to enact a legal framework recognising paternity leave as a component of social security, stressing that caregiving responsibilities must be shared between both parents.

Weight Loss Drugs Set to Flood India

Weight Loss Drugs Set to Flood India

Rediff.com   16 Mar 2026

While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.

US Business Schools Eye India Partnerships

US Business Schools Eye India Partnerships

Rediff.com   12 Mar 2026

The outreach comes amid a drop in Indian student enrolments in management programmes at American universities last year, following changes to US student visa policies.

Obesity Drug Can't Be Advertised Anymore

Obesity Drug Can't Be Advertised Anymore

Rediff.com   12 Mar 2026

'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'

India Targets 200,000 Foreign Students by 2030

India Targets 200,000 Foreign Students by 2030

Rediff.com   11 Mar 2026

The government has intensified its Study in India programme and is working closely with universities and states to achieve this goal.

Abbott Bets On Semaglutide Boom

Abbott Bets On Semaglutide Boom

Rediff.com   28 Feb 2026

Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.

CDSCO allows immediate lab testing of drugs to speed up approvals

CDSCO allows immediate lab testing of drugs to speed up approvals

Rediff.com   27 Feb 2026

The Centre has allowed companies to begin lab testing immediately after filing applications instead of waiting for detailed scrutiny, in a move to expedite approvals for manufacture, or import of new drugs.

Gurugram Dethrones Mumbai As India's Luxury Housing Capital

Gurugram Dethrones Mumbai As India's Luxury Housing Capital

Rediff.com   24 Feb 2026

Gurugram has overtaken Mumbai to become India's biggest luxury housing market in 2025, recording 24,120 crore in sales of homes priced above 10 crore.

Empty PG Seats, Missing Doctors

Empty PG Seats, Missing Doctors

Rediff.com   23 Feb 2026

'When young doctors see limited protection, unpredictable careers and an absence of institutional support, they hesitate.'

SC Slams RERA: 'Better to Abolish It'

SC Slams RERA: 'Better to Abolish It'

Rediff.com   13 Feb 2026

'Except facilitating builders in default, it is not doing anything else. Better to just abolish this institution.'

Indian pharma to get stronger dose of EU mkt access

Indian pharma to get stronger dose of EU mkt access

Rediff.com   5 Feb 2026

The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.

Realty to get indirect push from Budget proposals

Realty to get indirect push from Budget proposals

Rediff.com   3 Feb 2026

The government's Budget announcements providing tax holiday for data centres, setting up of city economic regions (CERs) and funding to improve infrastructure in Tier-II and -III cities may give an indirect boost to India's realty sector, said industry executives.

Centre mandates blue strip on antimicrobial drugs to curb overuse

Centre mandates blue strip on antimicrobial drugs to curb overuse

Rediff.com   24 Jan 2026

The Union health ministry has issued draft rules to mandate a blue vertical strip on all antimicrobial drug labels, aiming to rein in over-the-counter misuse and tackle India's growing antimicrobial resistance (AMR) problem.

Dr Reddy's profit down 14% on low Lenalidomide US sales

Dr Reddy's profit down 14% on low Lenalidomide US sales

Rediff.com   22 Jan 2026

Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.